8-K: Regulus Therapeutics Secures $100 Million in Oversubscribed Private Placement

Regulus Therapeutics has successfully completed a $100 million private placement to advance its microRNA-targeting drug pipeline.

Summary

• Regulus Therapeutics has entered into a securities purchase agreement for a private placement, raising approximately $100 million.
• The private placement includes the sale of 45,108,667 shares of common stock at $1.60 per share.
• Additionally, 173,915 shares of non-voting Class A-6 convertible preferred stock were sold at $160.00 per share.
• Each share of Class A-6 preferred stock is convertible into 100 shares of common stock, subject to certain ownership limitations.
• The private placement closed on March 14, 2024.
• The company plans to use the proceeds for non-clinical and clinical development activities and general corporate purposes.
• As of December 31, 2023, Regulus had $23.8 million in cash and cash equivalents.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful oversubscribed private placement and encouraging clinical trial data. The company has secured significant funding and is making progress in its drug development programs. However, the inherent risks of biotech investments and the company's development stage temper the sentiment slightly.

Positives

• The private placement was oversubscribed, indicating strong investor interest.
• The company secured a significant amount of funding to support its development programs.
• The participation of new and existing institutional investors validates the company's strategy.
• The company has a clear plan for the use of proceeds, focusing on drug development.
• The company has a potential accelerated approval pathway for its ADPKD treatment.

Negatives

• The company is relying on private funding, which may be dilutive to existing shareholders.
• The company's cash position was relatively low at $23.8 million before the raise.
• The company is still in the development stage and faces risks associated with clinical trials and regulatory approvals.

Risks

• The company is subject to risks associated with market conditions and the satisfaction of customary closing conditions.
• The company's drug development programs are novel and may not lead to marketable products.
• Clinical trials may not be successful, and regulatory approvals may not be granted.
• The company relies on third-party collaborators and faces risks related to intellectual property.
• The company needs additional capital to continue its operations.

Future Outlook

The company plans to use the proceeds from the private placement to advance its non-clinical and clinical development activities for its product candidates and for general corporate purposes. They also plan to increase the sample size of the cohort 4 fixed-dose open label enrollment up to 30 patients in order to further examine potential impact on cystic volume in patients with APDKD. The company anticipates a data readout from cohort 3 in mid-2024 and is screening patients for cohort 4 in 2Q 2024.

Management Comments

• Preston Klassen, M.D., President and Head of Research & Development of Regulus, stated that they are pleased with the data seen in the second cohort, in particular, the mechanistic dose response, as it continues to validate RGLS8429's potential efficacy in ADPKD.
• Jay Hagan, CEO of Regulus, mentioned that the data represents another important step on their way to bringing a potential treatment to those living with ADPKD.

Industry Context

This private placement reflects the ongoing interest in the biopharmaceutical sector, particularly in companies developing novel therapies for genetic diseases. The oversubscription suggests a positive market sentiment towards Regulus's approach to targeting microRNAs.

Comparison to Industry Standards

• The private placement is a common method for biotech companies to raise capital, especially those in the clinical development stage.
• The participation of well-known institutional investors like Adage Capital Partners, Deep Track Capital, and RA Capital Management is a positive signal, as these firms typically conduct thorough due diligence.
• The use of convertible preferred stock is a standard practice in private placements, offering investors downside protection and potential upside through conversion to common stock.
• The company's focus on microRNA therapeutics is a relatively new area of drug development, and the results of their clinical trials will be closely watched by the industry.

Related Party Transactions

• Stelios Papadopoulos, Ph.D., the company's Chairman of the Board, purchased 250,000 shares of common stock in the private placement.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability and ability to fund its programs.
• Patients with ADPKD may benefit from the development of a potential new treatment.
• Investors will have the opportunity to participate in the company's growth and potential success.

Next Steps

• The company will file a registration statement for the resale of the securities issued in the private placement.
• The company will continue its Phase 1b MAD study of RGLS8429, with data readout from cohort 3 anticipated in mid-2024.
• The company will start screening patients for cohort 4 in 2Q 2024.
• The company plans to increase the sample size of the cohort 4 fixed-dose open label enrollment up to 30 patients.

Key Dates

Keywords

private placement, equity financing, microRNA, RGLS8429, ADPKD, biopharmaceutical, convertible preferred stock, clinical trials, oligonucleotide, drug development